Open AccessA novel approach indirectly comparing benefit–risk balance across anti-thrombotic therapies in patients with atrial fibrillation
Author(s) -
Ariel Dogliotti,
Robert P. Giugliano
Publication year - 2015
Publication title -
european heart journal - cardiovascular pharmacotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.895
H-Index - 26
eISSN - 2055-6845
pISSN - 2055-6837
DOI - 10.1093/ehjcvp/pvu007
Subject(s) - medicine , rivaroxaban , edoxaban , dabigatran , atrial fibrillation , clopidogrel , aspirin , stroke (engine) , warfarin , randomized controlled trial , apixaban , placebo , relative risk , confidence interval , mechanical engineering , alternative medicine , pathology , engineering
Anti-thrombotic reduces thromboembolic events but increases bleeding in patients with atrial fibrillation (AF). We evaluated the benefit-risk of anti-platelet and anti-coagulant therapies, weighing these conflicting effects of treatment.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom